NCT05341089View on ClinicalTrials.gov

A Study of Two Different Formulations of LY3502970 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Healthy

Interventions

DRUG

LY3502970

Administered orally.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY